Refractory B-Cell Non-Hodgkin Lymphoma

Showing 1 - 25 of 32

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial

Not yet recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +5 more
  • Interferon Beta-1A
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin

Not yet recruiting
  • High Grade B-Cell Non-Hodgkin's Lymphoma
  • +3 more
  • Anti-CD19-CAR CMV-specific T-lymphocytes
  • +9 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

CB-Long-Term Safety Study (CB-LTSS)

Enrolling by invitation
  • Lymphoma, Non-Hodgkin
  • +7 more
  • Allogeneic CAR-T therapy
  • Irvine, California
  • +3 more
Nov 18, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston

Recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • +4 more
  • CD19.CAR-aNKT cells
  • +2 more
  • Houston, Texas
  • +1 more
Aug 19, 2022

Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,

Recruiting
  • Lymphoma, Non-Hodgkin
  • +6 more
  • CB-010
  • +2 more
  • Scottsdale, Arizona
  • +7 more
Aug 19, 2022

Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +3 more
  • Allogeneic Bone Marrow Transplantation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Loncastuximab Tesirine
  • +4 more
  • Pembroke Pines, Florida
  • +19 more
Jul 22, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jul 14, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle

Not yet recruiting
  • Post-Transplant Lymphoproliferative Disorder
  • +10 more
  • Loncastuximab Tesirine
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Hodgkin Lymphoma Trial in New York (Decitabine and

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +5 more
  • Decitabine and Cedazuridine
  • Nivolumab
  • New York, New York
    NY011 Laura and Isaac Perlmutter Cancer Center at NYU Langone
Jul 8, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor

Recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • New Haven, Connecticut
    Yale University Cancer Center LAO
Jun 29, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in France (Selicrelumab, Atezolizumab)

Terminated
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Créteil, France
  • +4 more
Jul 23, 2021

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia Trial in Chengdu (Modified anti-CD19 CAR T cells)

Active, not recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Refractory Leukemia
  • Modified anti-CD19 CAR T cells
  • Chengdu, Sichuan, China
    Sichuan University
Mar 17, 2021

Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai, Hangzhou (CAR-CD19 T Cells)

Recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Relapsed B-cell Non-Hodgkin Lymphoma
  • CAR-CD19 T Cells
  • Shanghai, Shanghai, China
  • +1 more
Oct 7, 2020